Pharmaceutical and Biotech Public RelationsHTG
High Throughput Genomics, Inc., (HTG), is a provider of transcriptomic technology and services. HTG’s technology opens a new era of drug discovery and allows companies to identify new drug compounds, quickly eliminate less promising compounds and bring new drugs to market faster. HTG is the first company to commercialize this technology. HTG is online at www.htgenomics.com.
The leader in on-demand innovation.
Scancell was to start Phase I trials in Nottingham, UK for a new generation of highly-effective immunotherapy approaches for treating an existing cancer and preventing reoccurrence. The challenge for Schwartz was to explain the complex technology involved in DNA vaccines and distinguish Scancell’s melanoma candidate treatment from two other melanoma vaccines currently in trials.